DOCSLIB.ORG

FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models Published OnlineFirst April 28, 2020; DOI: 10.1158/1078-0432.CCR-19-2958 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models A C Matthew A. Lakins, Alexander Koers, Raffaella Giambalvo, Jose Munoz-Olaya, Robert Hughes, Emma Goodman, Sylwia Marshall, Francisca Wollerton, Sarah Batey, Daniel Gliddon, Mihriban Tuna, and Neil Brewis ABSTRACT ◥ Purpose: With the increased prevalence in checkpoint therapy Results: We demonstrated simultaneous binding of CD137 þ resistance, there remains a significant unmet need for additional andPD-L1andshowedpotentT-cell activation across CD8 therapies for patients with relapsing or refractory cancer. We have T-cell activation assays in a PD-L1–dependent manner with a developed FS222, a bispecific tetravalent antibody targeting CD137 CD137/PD-L1 bispecific antibody, FS222. FS222 also activated and PD-L1, to induce T-cell activation to eradicate tumors without T cells in a human primary mixed lymphocyte reaction assay, with the current toxicity and efficacy limitations seen in the clinic. greater potency than the monospecific mAb combination. FS222 Experimental Design: A bispecific antibody (FS222) was devel- showed no signs of liver toxicity up to 30 mg/kg in a non-human oped by engineering CD137 antigen–binding sites into the Fc region primate dose-range finding study. A surrogate molecule caused of a PD-L1 IgG1 mAb. T-cell activation by FS222 was investigated significant tumor growth inhibition and survival benefit, concom- þ using multiple in vitro assays. The antitumor efficacy, survival itant with CD8 T-cell activation, in CT26 and MC38 syngeneic benefit, pharmacodynamics, and liver pharmacology of a murine mouse tumor models. surrogate molecule were assessed in syngeneic mouse tumor mod- Conclusions: By targeting CD137 agonism to areas of PD-L1 els. Toxicology and the pharmacokinetic/pharmacodynamic profile expression, predominantly found in the tumor microenvironment, of FS222 were investigated in a non-human primate dose-range FS222 has the potential to leverage a focused, potent, and safe finding study. immune response augmenting the PD-(L)1 axis blockade. Introduction T cells, and dendritic cells (DC; ref. 4). Engagement of CD137 by its ligand CD137L results in receptor trimer formation, and subsequent Immunomodulatory mAbs are a promising approach for patients clustering leads to CD137 signaling cascade activation. This provides a with cancer. Immune checkpoint inhibitors targeting programmed cell survival signal to T cells, thereby sustaining effective T-cell activation death (PD)-1, PD-L1, and cytotoxic T-lymphocyte–associated protein and generation of immunologic memory. The primary functional role 4 are the most advanced immunotherapy agents for oncology. How- of CD137 in enhancing T-cell cytotoxicity was first described in ever, only a subset of patients benefit from long-term survival, and 1997 (5), and soon thereafter CD137 mAbs were proposed as anti- there remains an unmet clinical need (1). Although bispecific T-cell cancer therapeutics. engagers, such as blinatumomab (BLINCYTO) targeting CD3 and Clinical development of CD137 mAbs has been hampered by dose- CD19, are the most advanced next-generation immuno-oncology limiting high-grade liver inflammation associated with CD137 agonist modalities, their use is limited to hematologic malignancies and antibody treatment. Urelumab (Bristol-Myers Squibb, BMS-663513), further limited by acute safety concerns (2). We believe agonist a human IgG4 isotype antibody, was the first CD137 mAb to enter antibodies against specific costimulatory receptors from the tumor clinical trials, but these were halted after significant, on target, dose- necrosis factor receptor superfamily may represent the next stage in dependent liver toxicity was observed (6–8). This outcome was not solid cancer treatment. predicted because urelumab failed to preclinically identify liver inflam- CD137 (4-1BB) is a costimulatory molecule and widely known to þ mation due to its low affinity for the cynomolgus monkey target be upregulated on CD8 T cells following activation (3). CD137 þ molecule (9). More recently, clinical trials of urelumab in the treatment can also be expressed on activated CD4 helper T cells, B cells, of solid cancers were recommended; however, urelumab dosing in regulatory T cells (Treg), natural killer (NK) cells, natural killer these trials had to be limited and efficacy results were disappointing with no objective response reported in the 64 patients with solid F-star Therapeutics Ltd., Cambridge, United Kingdom. tumors treated with monotherapy (6). No dose-limiting toxicity has been observed with CD137 mAb Note: Supplementary data for this article are available at Clinical Cancer fi Research Online (http://clincancerres.aacrjournals.org/). utomilumab (PF-05082566, P zer), a human IgG2 isotype antibody, in dose-escalation phase I clinical trials dosing up to 10 mg/kg in phase I Corresponding Author: Matthew A. Lakins, F-star Therapeutics Ltd., Eddeva clinical trials of advanced cancer (6, 8). However, the overall objective B920, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom. Phone: 01223948159; Fax: 01223410493; E-mail: [email protected] response rate with this antibody was only 3.8% in patients with solid tumors, potentially indicating that utomilumab has a weaker potency Clin Cancer Res 2020;26:4154–67 and clinical efficacy than urelumab, while having a more favorable doi: 10.1158/1078-0432.CCR-19-2958 safety profile (6, 8). Trials of utomilumab in combination with Ó2020 American Association for Cancer Research. radiotherapy or chemotherapy, as well as in combination with other AACRJournals.org | 4154 Downloaded from clincancerres.aacrjournals.org on September 25, 2021. © 2020 American Association for Cancer Research. Published OnlineFirst April 28, 2020; DOI: 10.1158/1078-0432.CCR-19-2958 Characterization of a CD137/PD-L1 Bispecific Antibody cancer without toxicity (7, 8), we believe there remains a need to Translational Relevance develop treatments that combine PD-L1 blockade and provoke We developed an mAb2 bispecific antibody for targeting CD137 strong CD137 agonism in safe and efficacious therapies that do not þ and PD-L1 in solid tumors which potently activated CD8 T cells rely on a combination approach. An alternative to combining CD137 in vitro only in the presence of PD-L1–expressing cells. Our and PD-L1 monotherapies is the development of a bispecific antibody þ surrogate molecule activated intratumoral CD8 T cells and that encompasses the two modalities. It is anticipated that such a effectively controlled tumor growth in syngeneic mouse tumor bispecific mAb could deliver superior antitumor efficacy over com- þ models without toxicity. We found that FS222 activates CD4 and bining monotherapies. There are existing preclinical approaches com- þ CD8 T cells in vitro with activity superior to the combination of bining CD137 mAb activity with PD-L1 mAb activity into bispecific monospecific, mAbs representative of those used in the clinic therapies. These can be subdivided into two broad range categories, currently, providing evidence that our tetravalent bispecific clinical non–IgG- and IgG-like molecules, both of which can be further candidate will provide greater benefit to patients than a combina- divided by their binding valency for each target. tion approach against both targets in solid tumors. Considering the Here, we describe a fully human, tetravalent, IgG bispecific antibody broad expression of PD-L1 in many solid tumors, FS222 may (mAb2, FS222) comprising a PD-L1–specific mAb with 5 amino acid provide therapeutic opportunities for patients with cancer who insertions and 7 amino acid substitutions in the CH3 region of the Fc remain challenging to treat. domain to create two binding sites forming an Fc fragment antigen- binding (Fcab) for CD137 (15). FS222 blocked PD-L1 and activated þ CD137 tumor-reactive T cells in a PD-L1–dependent manner. It demonstrated similar potency in primates, and preliminary toxicity antibody therapies, are ongoing with early results showing no dose- studies in this species showed significant pharmacodynamic (PD) limiting toxicities for doses up to 5 mg/kg and a 26% patient response responses and a lack of toxicity. A surrogate mouse cross-reactive rate for the combination of utomilumab and pembrolizumab (10). CD137/PD-L1 mAb2 with homologous mechanisms of action to PD-1 and its ligands PD-L1 (CD274, B7-H1) and PD-L2 (B7-DC) FS222 was observed to provide a substantial survival benefit in multiple deliver inhibitory signals that regulate the balance between T-cell mouse tumor models with no toxicity and showed potent in vivo PD activation, tolerance, and immunopathology. Consequently, PD-L1 changes related to antitumor immune responses. expression by cells can mediate protection against cytotoxic T lym- phocyte killing. Cancer, as a chronic and proinflammatory disease, subverts this immune-protective pathway through upregulation of Materials and Methods PD-L1 expression to evade the host immune response. PD-L1 expres- Production and characterization of a CD137/PD-L1 mAb2, sion has been shown in a wide variety of solid tumors (11), and clinical FS222 trials have shown the benefit of targeting PD-L1 in patients leading to The CD137/PD-L1 mAb2 molecule named FS222 consisting of the approval of three PD-L1–targeting mAbs to date: atezolizumab an IgG1 molecule comprising the
Load more

Recommended publications
  • TRAIL and Cardiovascular Disease—A Risk Factor Or Risk Marker: a Systematic Review
    Journal of Clinical Medicine Review TRAIL and Cardiovascular Disease—A Risk Factor or Risk Marker: A Systematic Review Katarzyna Kakareko 1,* , Alicja Rydzewska-Rosołowska 1 , Edyta Zbroch 2 and Tomasz Hryszko 1 1 2nd Department of Nephrology and Hypertension with Dialysis Unit, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] (A.R.-R.); [email protected] (T.H.) 2 Department of Internal Medicine and Hypertension, Medical University of Białystok, 15-276 Białystok, Poland; [email protected] * Correspondence: [email protected] Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a pro-apoptotic protein showing broad biological functions. Data from animal studies indicate that TRAIL may possibly contribute to the pathophysiology of cardiomyopathy, atherosclerosis, ischemic stroke and abdomi- nal aortic aneurysm. It has been also suggested that TRAIL might be useful in cardiovascular risk stratification. This systematic review aimed to evaluate whether TRAIL is a risk factor or risk marker in cardiovascular diseases (CVDs) focusing on major adverse cardiovascular events. Two databases (PubMed and Cochrane Library) were searched until December 2020 without a year limit in accor- dance to the PRISMA guidelines. A total of 63 eligible original studies were identified and included in our systematic review. Studies suggest an important role of TRAIL in disorders such as heart failure, myocardial infarction, atrial fibrillation, ischemic stroke, peripheral artery disease, and pul- monary and gestational hypertension. Most evidence associates reduced TRAIL levels and increased TRAIL-R2 concentration with all-cause mortality in patients with CVDs. It is, however, unclear Citation: Kakareko, K.; whether low TRAIL levels should be considered as a risk factor rather than a risk marker of CVDs.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Role of ADAM10 and ADAM17 in Regulating CD137 Function
    International Journal of Molecular Sciences Article Role of ADAM10 and ADAM17 in Regulating CD137 Function Jana Seidel 1, Sinje Leitzke 1, Björn Ahrens 1, Maria Sperrhacke 1, Sucharit Bhakdi 2 and Karina Reiss 1,* 1 Department of Dermatology, University of Kiel, 24105 Kiel, Germany; [email protected] (J.S.); [email protected] (S.L.); [email protected] (B.A.); [email protected] (M.S.) 2 Independent Researcher, 24105 Kiel, Germany; [email protected] * Correspondence: [email protected] Abstract: Human CD137 (4-1BB), a member of the TNF receptor family, and its ligand CD137L (4-1BBL), are expressed on immune cells and tumor cells. CD137/CD137L interaction mediates bidirectional cellular responses of potential relevance in inflammatory diseases, autoimmunity and oncology. A soluble form of CD137 exists, elevated levels of which have been reported in patients with rheumatoid arthritis and various malignancies. Soluble CD137 (sCD137) is considered to represent a splice variant of CD137. In this report, however, evidence is presented that A Disintegrin and Metalloproteinase (ADAM)10 and potentially also ADAM17 are centrally involved in its generation. Release of sCD137 by transfected cell lines and primary T cells was uniformly inhibitable by ADAM10 inhibition. The shedding function of ADAM10 can be blocked through inhibition of its interaction with surface exposed phosphatidylserine (PS), and this effectively inhibited sCD137 generation. The phospholipid scramblase Anoctamin-6 (ANO6) traffics PS to the outer membrane and thus modifies ADAM10 function. Overexpression of ANO6 increased stimulated shedding, and hyperactive ANO6 led to maximal constitutive shedding of CD137.
    [Show full text]
  • CLINICAL RESEARCH PROJECT Protocol #11-H-0134 Drug Name: Eltrombopag (Promacta®) IND Number: 104,877 IND Holder: NHLBI OCD Date: January 2, 2019
    CLINICAL RESEARCH PROJECT Protocol #11-H-0134 Drug Name: eltrombopag (Promacta®) IND number: 104,877 IND holder: NHLBI OCD Date: January 2, 2019 Title: A Pilot Study of a Thrombopoietin-receptor Agonist (TPO-R agonist), Eltrombopag, in Moderate Aplastic Anemia Patients Other Identifying Words: Hematopoiesis, autoimmunity, thrombocytopenia, neutropenia, anemia, stem cells, cytokine, Promacta® (eltrombopag) Protocol Principal Investigator: *Cynthia E. Dunbar, M.D., TSCBB, NHLBI (E) Medically and Scientifically Responsible Investigator: *Cynthia E. Dunbar, M.D., TSCBB, NHLBI (E) Associate Investigators: *Georg Aue, M.D., OCD, NHLBI (E) *Neal S. Young, M.D., Chief, HB, NHLBI (E) *André Larochelle, M.D., Ph.D., CMTB, NHLBI (E) David Young, M.D., TSCBB, NHLBI (E) Susan Soto, M.S.N., R.N., Research Nurse, OCD, NHLBI(E) Olga Rios, RN, Research Nurse, OCD, NHLBI (E) Evette Barranta, R.N, Research Nurse, OCD, NHLBI (E) Jennifer Jo Kyte, DNP, Research Nurse, OCD, NHLBI (E) Colin Wu, PhD, Biostatistician, OBR, NHLBI (E) Xin Tian, PhD, Biostatistician, OBR/NHLBI (E) *Janet Valdez, MS, PAC, OCD, NHLBI (E) *Jennifer Lotter, MSHS, PA-C., OCD, NHLBI (E) Qian Sun, Ph.D., DLM, CC (F) Xing Fan, M.D., HB, NHLBI (F) Non-NIH, Non-Enrolling Engaged Investigators: Thomas Winkler, M.D., NHLBI, HB (V)# # Covered under the NIH FWA Independent Medical Monitor: John Tisdale, MD, NHLBI, OSD 402-6497 Bldg. 10, 9N116 * asterisk denotes who can obtain informed consent on this protocol Subjects of Study: Number Sex Age-range 38 Either ≥ 2 years and weight >12 kg Project Involves Ionizing Radiation? No (only when medically indicated) Off-Site Project? No Multi center trial? No DSMB Involvement? Yes 11-H-0134 1 Cynthia E.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • RANK Receptor Oligomerisation in the Regulation of Nfkb Signalling
    S DAS and others RANK oligomerisation and 53:1 81–91 Research signalling Open Access RANK receptor oligomerisation in the regulation of NFkB signalling Correspondence S Das, I Sepahi, A Duthie, S Clark and J C Crockett should be addressed to J C Crockett Bone and Musculoskeletal Research Programme, Division of Applied Medicine, Institute of Medical Sciences, Email University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK [email protected] Abstract The interaction of receptor activator of NFkB (RANK), a member of the tumour necrosis Key Words factor receptor superfamily, with RANK ligand is crucial for the formation, function and " oligomerisation survival of osteoclasts. The role of the cytoplasmic oligomerisation domain (pre-ligand " RANK assembly domain; PLAD or ‘IVVY’ motif) in the ligand-dependent activation of downstream " NFkB NFkB signalling has not been studied previously. The discovery of truncating mutations of " osteopetrosis TNFRSF11A (W434X and G280X that lack the PLAD) as the cause of rare cases of osteoclast- poor osteopetrosis offered the opportunity for functional study of this region. Recapitu- lating the W434X mutation by transcription activator-like effector nuclease (TALEN)- mediated targeted disruption of Tnfrsf11a within the region homologous to W434X in the mouse macrophage-like cell line RAW264.7 impaired formation of osteoclast-like cells. Using overexpression studies, we demonstrated that, in contrast to WT-RANK, the absence of the PLAD in G280X-RANK and W434X-RANK prevented ligand-independent but not ligand- dependent oligomerisation. Cells expressing W434X-RANK, in which only two of the three TRAF6-binding motifs are present, continued to exhibit ligand-dependent NFkB signalling.
    [Show full text]
  • T Lymphocytes in the Synovial Fluid of Patients with Active Rheumatoid
    Clinical and Experimental Rheumatology 2001; 19: 317-320. BRIEF PAPER T lymphocytes in the ABSTRACT in the pathogenesis of the disease (4). Objective. To assess the percentage of The human CD 134 (OX40) cell sur- synovial fluid of patients T ly m p h o cy t e s , b e a ring CD134, a faceantigen, a 50-kDa membrane-asso- with active rheumatoid member of the TNF receptor superfam - ciated glycoprotein, is a member of the arthritis display CD134- i ly, p ri m a ri ly found on autore a c t ive tumor necrosis factor (TNF) receptor CD4+ T cells in the peripheral blood superfamily, which is found primarily OX40 surface antigen (PB) and synovial fluid (SF) of rheu - on activated CD4+ cells and not on matoid arthritis (RA) patients. normal resting peripheral blood lym- R. Giacomelli, M e t h o d s . The surface ex p ression of phocytes (5). Its interaction with the A. Passacantando, CD134 on SF and PB mononu cl e a r specific ligand (CD134L – OX40L), a 1 cells was performed by flow cytometry type II membrane protein (6) generally R. Perricone , in 25 RA patients and correlated to the expressed on activated B lymphocytes I. Parzanese, M. Rascente, disease activity. (7), antigen presenting cells, and acti- G. Minisola2, G. Tonietti Results. CD134 expression on CD3+, vated endothelial cells (8) is, on one CD4+, CD8+ and CD25+ cells was hand, an efficient costimulatory signal Clinica Medica, University of L’Aquila; higher in SF than in PB of RA patients for CD4+ T cell-dependent humora l 1Immunologia Clinica, University of Tor ( P < 0.001).
    [Show full text]
  • Jimmunol.1601908.Full.Pdf
    Metabolic Reprogramming Commits Differentiation of Human CD27 +IgD+ B Cells to Plasmablasts or CD27−IgD− Cells This information is current as Masataka Torigoe, Shigeru Iwata, Shingo Nakayamada, Kei of October 3, 2021. Sakata, Mingzeng Zhang, Maiko Hajime, Yusuke Miyazaki, Manabu Narisawa, Koji Ishii, Hirotaka Shibata and Yoshiya Tanaka J Immunol published online 16 June 2017 http://www.jimmunol.org/content/early/2017/06/15/jimmun ol.1601908 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/06/15/jimmunol.160190 Material 8.DCSupplemental http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 3, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published June 16, 2017, doi:10.4049/jimmunol.1601908 The Journal of Immunology Metabolic Reprogramming Commits Differentiation of Human CD27+IgD+ B Cells to Plasmablasts or CD272IgD2 Cells Masataka Torigoe,*,† Shigeru Iwata,* Shingo Nakayamada,* Kei Sakata,*,‡ Mingzeng Zhang,* Maiko Hajime,* Yusuke Miyazaki,* Manabu Narisawa,* Koji Ishii,† Hirotaka Shibata,† and Yoshiya Tanaka* B cells play a crucial role in the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE).
    [Show full text]
  • Lipid Rafts Are Important for the Association of RANK and TRAF6
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 35, No. 4, 279-284, August 2003 Lipid rafts are important for the association of RANK and TRAF6 Hyunil Ha1,3, Han Bok Kwak1,2,3, Introduction Soo Woong Lee1,2,3, Hong-Hee Kim2,4, 1,2,3,5 Osteoclasts are multinucleated giant cells responsible and Zang Hee Lee for bone resorption. These cells are differentiated from 1 hematopoietic myeloid precursors of the monocyte/ National Research Laboratory for Bone Metabolism macrophage lineage (Suda et al., 1992). For the dif- 2Research Center for Proteineous Materials 3 ferentiation of osteoclast precursors into mature osteo- School of Dentistry clasts, a cell-to-cell interaction between osteoclast Chosun University, Gwangju 501-759, Korea 4 precursors and osteoblasts/stromal cells are required Department of Cell and Developmental Biology (Udagawa et al., 1990). Recently, many studies have College of Dentistry, Seoul National University provided ample evidences that the TNF family mem- Seoul 110-749, Korea κ 5 ber RANKL (receptor activator of NF- B ligand; also Corresponding author: Tel, 82-62-230-6872; known as ODF, OPGL, and TRANCE) is expressed Fax, 82-62-227-6589; E-mail, [email protected] on the surface of osteoblasts/stromal cells and es- sential for osteoclast differentiation (Anderson et al., Accepted 19 June 2003 1997; Yasuda et al., 1998; Takahashi et al., 1999). When its receptor RANK was stimulated by RANKL, Abbreviations: MAPK, mitogen-activated protein kinase; MCD, several TNF receptor-associated factors (TRAFs), methyl-β-cyclodextrin; RANK, receptor activator of NF-κB; TLR, especially TRAF6, can be directly recruited into RANK Toll-like receptor; TNFR, TNF receptor; TRAF, TNF receptor- cytoplasmic domains and may trigger downstream associated factor signaling molecules for the activation of NF-κB and mitogen activated protein kinases (MAPKs) (Darnay et al., 1998; Wong et al., 1998; Kim et al., 1999).
    [Show full text]
  • High TNFRSF12A Level Associated with MMP-9 Overexpression Is
    RESEARCH ARTICLE High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set enrichment analysis and validation in large-scale cohorts Jungho Yang1, Kyueng-Whan Min2*, Dong-Hoon Kim1*, Byoung Kwan Son3, Kyoung Min Moon4, Young Chan Wi5, Seong Sik Bang5, Young Ha Oh2, Sung-Im Do1, Seoung Wan Chae1, Sukjoong Oh6, Young Hwan Kim7, Mi Jung Kwon8 a1111111111 1 Departments of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, a1111111111 Seoul, Republic of Korea, 2 Department of Pathology, Hanyang University Guri Hospital, Hanyang University a1111111111 College of Medicine, Guri, Gyeonggi-do, Republic of Korea, 3 Department of Internal Medicine, Eulji Hospital, a1111111111 Eulji University School of Medicine, Seoul, Republic of Korea, 4 Department of Internal Medicine, Gangneung a1111111111 Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea, 5 Department of Pathology, Hanyang University College of Medicine, Seoul, Republic of Korea, 6 Departments of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 7 Departments of Nuclear Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 8 Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Gyeonggi-do, Republic of Korea OPEN ACCESS * [email protected](KWM); [email protected](DHK) Citation: Yang J, Min K-W, Kim D-H, Son BK, Moon KM, Wi YC, et al. (2018) High TNFRSF12A level associated with MMP-9 overexpression is linked to poor prognosis in breast cancer: Gene set Abstract enrichment analysis and validation in large-scale cohorts.
    [Show full text]
  • The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses in Vivo
    The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo This information is current as Xueli Yuan, Alan D. Salama, Victor Dong, Isabela Schmitt, of September 27, 2021. Nader Najafian, Anil Chandraker, Hisaya Akiba, Hideo Yagita and Mohamed H. Sayegh J Immunol 2003; 170:2949-2955; ; doi: 10.4049/jimmunol.170.6.2949 http://www.jimmunol.org/content/170/6/2949 Downloaded from References This article cites 51 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/170/6/2949.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo1 Xueli Yuan,* Alan D. Salama,* Victor Dong,* Isabela Schmitt,* Nader Najafian,* Anil Chandraker,* Hisaya Akiba,† Hideo Yagita,† and Mohamed H.
    [Show full text]
  • Double-Negative (CD27-Igd-) B Cells Are Expanded in NSCLC And
    Centuori et al. J Transl Med (2018) 16:30 https://doi.org/10.1186/s12967-018-1404-z Journal of Translational Medicine RESEARCH Open Access Double‑negative ­(CD27−IgD−) B cells are expanded in NSCLC and inversely correlate with afnity‑matured B cell populations Sara M. Centuori1, Cecil J. Gomes2, Samuel S. Kim3, Charles W. Putnam1,3, Brandon T. Larsen4, Linda L. Garland1,5, David W. Mount6 and Jesse D. Martinez1,7* Abstract Background: The presence of B cells in early stage non-small cell lung cancer (NSCLC) is associated with longer survival, however, the role these cells play in the generation and maintenance of anti-tumor immunity is unclear. B cells diferentiate into a variety of subsets with difering characteristics and functions. To date, there is limited informa- tion on the specifc B cell subsets found within NSCLC. To better understand the composition of the B cell populations found in NSCLC we have begun characterizing B cells in lung tumors and have detected a population of B cells that are ­CD79A+CD27−IgD−. These ­CD27−IgD− (double-negative) B cells have previously been characterized as uncon- ventional memory B cells and have been detected in some autoimmune diseases and in the elderly population but have not been detected previously in tumor tissue. Methods: A total of 15 fresh untreated NSCLC tumors and 15 matched adjacent lung control tissues were dissociated and analyzed by intracellular fow cytometry to detect the B cell-related markers CD79A, CD27 and IgD. All ­CD79A+ B cells subsets were classifed as either naïve ­(CD27−IgD+), afnity-matured ­(CD27+IgD−), early memory/germinal center cells ­(CD27+IgD+) or double-negative B cells ­(CD27−IgD−).
    [Show full text]